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Abstract 
In patients with cancer, opioids are principally used for the management of acute surgical and 
chronic cancer-related pain. However, opioids have many non-analgesic effects, including 
direct and indirect effects on cancer cells and on anti-tumour immunity (natural killer (NK) 
cells, macrophages and T-cells). Direct effects on immune cells are manifested via opioid and 
non-opioid Toll-like receptors, whereas indirect effects are manifested via the sympathetic 
nervous system and hypothalamic-pituitary-adrenal axis. Opioids can also decrease/alter 
immune cell infiltration into the tumour microenvironment. Animal models have shown that 
this is not a class effect, in that morphine and fentanyl suppress NK cell cytotoxicity; 
buprenorphine does not affect NK cell cytotoxicity, whereas tramadol increases NK cell 
cytotoxicity, reducing metastasis. In healthy individuals, morphine suppresses and fentanyl 
enhances NK cell cytotoxicity. In patients undergoing surgery, fentanyl decreased and 
tramadol increased NK cell cytotoxicity; clinical outcomes were not determined. Meta-
analyses of opioid-sparing surgical studies report an association between improved 
recurrence-free and/or overall survival with regional/neuraxial anaesthesia compared with 
systemic opioids. In patients receiving opioids for non-surgical cancer-related pain, morphine 
has variable effects on immunity; clinical outcomes were not assessed. Although there is a 
potential association between systemic opioid administration and shorter survival in cancer 
patients with a prognosis of months to years, studies have not been designed to primarily 
assess survival, as a consequence of which causality cannot be apportioned. Pain is 
immunosuppressive, so analgesia is important. Opioids for cancer-related pain will continue 
to be recommended until definitive data on the effects of opioids on clinical outcomes in 
specific patient groups becomes available. 
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Abbreviations  
GAB1: GRB2 Associated Binding Protein 1 
HPA: hypothalamic pituitary adrenal  
IVME: intravenous morphine-equivalent dose 
MOP: mu opioid peptide  
NK cells: natural killer cells 
NPY: neuropeptide Y  
PAG: periaqueductal gray  
PCR: polymerase chain reaction 
PI3 kinase: Phosphoinositide 3-kinase 
SNS: sympathetic nervous system  
STAT3: signal transducer and activator of transcription-3 
TLR-4: Toll-like receptor-4  
 
 
Plain Language Summary 
Some opioids influence the functioning of the immune system, and this has been shown to 
affect cancer growth and progression in animal models. Although some opioids affect 
different aspects of immune function in humans, their effect on the cancer or the patient 
remains unknown. However, some of the surgical studies to date report an association 
between improved clinical outcomes with lower doses of systemic opioids. Pain suppresses 
immunity and immunity is important for protecting against cancer. Despite the uncertainty, 
adequate control of cancer-related pain is important and opioids will therefore continue to be 
recommended for its management. 
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Opioids and the immune system  
Opioids are a diverse range of drugs that act on opioids receptors. In patients with cancer, 
opioids are principally used for the management of cancer-related pain in the long-term, and 
cancer surgery pain in the shorter term. As with all drugs, opioids can elicit a range of 
undesired consequences (Boland et al., 2013), including the functioning of the immune 
system (Grace et al., 2015; Ramaswamy et al., 2017; Wigmore et al., 2016). 
The immune system has a crucial role in controlling and potentially eradicating cancer cells 
in individuals with, or developing, cancer. Many immune cells are involved in anti-tumour 
immunity including natural killer (NK) cells, T cells, mast cells, dendritic cells and 
macrophages, as well as soluble immune mediators such as cytokines and chemokines (Table 
1) (Boland et al., 2014b; Liang et al., 2016; Nguyen et al., 2014). NK cell activity is a critical 
endpoint in the immunotoxicological evaluation of pharmaceuticals (Agency, 2000) and a 
consensus statement for the use of opioids for alleviating chronic pain in elderly people 
proposes that the effects of opioids on immune function should be considered (Pergolizzi et 
al., 2008).  
Given that patients with cancer are also at risk of infection, it is important that the anti-
infection arm of the immune system is maintained at an effective level. However, there is 
evidence that opioids could increase the risk of infection in patients with cancer (Shao et al., 
2017; Suzuki et al., 2013), as a retrospective study has shown that patients treated with 
morphine developed more infections than those treated with oxycodone (Suzuki et al., 2013). 
Furthermore, the risk of infection has been shown to increase by 2% for each 10 mg rise in 
the oral morphine equivalent daily dose; with no difference between opioids (Shao et al., 
2017).  
Opioids can influence the establishment and progression of cancer in many ways, including 
indirect effects on cancer growth via angiogenesis and host immunity (Afsharimani et al., 
2011; Gach et al., 2011; Gupta et al., 2002; Koodie et al., 2014). Opioids also have the 
potential to directly influence the growth of cancer cells, as cancer tissue overexpresses mu 
opioid peptide receptors (MOP) (Lennon et al., 2012; Mathew et al., 2011; Nguyen et al., 
2014; Singleton et al., 2014). Overexpression of the MOP receptor on cancer cells in murine 
models has been shown to increase the growth of lung cancer (Lennon et al., 2014), and 
decreasing MOP receptor activity (using MOP receptor small hairpin RNA mice or the opioid 
receptor antagonist methylnaltrexone) has been shown to reduce the growth of lung cancer 
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(Mathew et al., 2011). Furthermore, MOP receptor overexpression has been associated with 
the development of metastasis in patients with prostate, oesophageal and lung cancer 
(Singleton et al., 2014; Zhang et al., 2015; Zylla et al., 2013). Morphine influences the 
proliferation and survival of cancer cells via direct effects on tumour cell DNA cleavage, 
mitogen-activated protein kinase, Src, Gab-1, PI3 kinase, Akt and STAT3 signalling 
pathways (Lennon et al., 2014; Lennon et al., 2012; Mathew et al., 2011). 
The remainder of this review will concentrate on the cancer-related immune effects of 
opioids. Drug/molecular target nomenclature conforms to British Journal of Pharmacology's 
Concise Guide to Pharmacology (Alexander et al., 2015).  
 
Mechanisms of immune effects of opioids  
Numerous mechanisms underlying the influence of opioids on immune cells have been 
described (Figure 1). In vivo, opioids can modulate immune function by direct effects on 
immune cells, and via indirect effects which involve the central nervous system and its 
release of immune mediators (Al-Hashimi et al., 2013; Borner et al., 2008; Campana et al., 
2010).  
For opioids to have direct effects on immune cells, immune cells must express opioid 
receptors, or opioids must be able to have effects via non-opioid receptors present on immune 
cells (e.g. Toll-like receptor-4) (Xie et al., 2017). Although morphine can directly interact 
with MOP receptors on immune cells in vitro (Borner et al., 2008), the presence of functional 
opioid receptors on immune cells, as determined using radioligand antibody binding studies, 
Western blot and polymerase chain reaction (PCR) analysis continues to be disputed (Al-
Hashimi et al., 2016; Al-Hashimi et al., 2013; Borner et al., 2009; Campana et al., 2010; 
Glattard et al., 2010; Kraus, 2009; Langsdorf et al., 2011; Williams et al., 2007). One 
possibility for the discrepancy is that MOP receptor expression depends upon immune cell 
activation, in that the expression of MOP receptors in T cells is non-constitutive (Borner et 
al., 2008). In activated human T cells, MOP receptor mRNA is increased to levels about 1% 
of those in neurons and can produce functional MOP receptors in T cells (Borner et al., 
2007). Many extracellular signals, including the cytokines IL-1, IL-4, IL-6, TNF and IFN-, 
control MOP receptor gene transcription and cell surface opioid receptor expression in 
immune cells (Kraus, 2009; Langsdorf et al., 2011). Toll-like receptor-4 is involved in innate 
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immune system activation. In vitro and in silico techniques have shown that many commonly 
used opioids can have direct effects on innate immunity via activation of the Toll-like 
receptor-4 (Franchi et al., 2012; Grace et al., 2015; Hutchinson et al., 2010; Khabbazi et al., 
2016).  
There are two principal pathways via which the central immunosuppressive effects of 
morphine can be mediated. These effects have been primarily identified on the basis of 
animal model-derived data and might therefore differ between species (Al-Hashimi et al., 
2013; Fecho et al., 1996). Acute morphine administration acts on the peri-aqueductal gray 
and sympathetic nervous system (which innervates lymphoid organs) to release 
immunosuppressive biological amines that can suppress NK cell cytotoxicity (Fecho et al., 
1996; Gomez-Flores et al., 2000; Hernandez et al., 1993; Irwin et al., 1988; Weber et al., 
1989). An additional arm to the sympathetic nervous system pathway is the action of acute 
morphine/diamorphine via D1 receptors in the nucleus accumbens shell. This increases the 
release of neuropeptide Y from the sympathetic nervous system, which in turn acts on 
peripheral Y1 receptors to inhibit splenic NK cell cytotoxicity (Saurer et al., 2009; Saurer et 
al., 2006). Prolonged use of opioids increases activity in the hypothalamic-pituitary-adrenal 
axis, thereby increasing the release of immunosuppressive glucocorticoids, and decreasing T 
cell function and NK cell cytotoxicity. As pain/stress activates this axis, opioids used as 
analgesics might be protective (Borman et al., 2009; Hernandez et al., 1993; Mellon et al., 
1998; Zhang et al., 2011).  
As well as having direct and indirect effects on immune cell activation, MOP receptor 
activation can inhibit NK cell migration. Fewer NK cells are in the tumours of wild-type 
compared to MOP receptor knockout mice (Boehncke et al., 2011). Morphine has been 
shown to reduce leukocyte migration in a murine lung tumour model (Koodie et al., 2014), 
and NK cell infiltration into breast cancer tissue is decreased in women who have received 
more perioperative systemic opioids (Desmond et al., 2015). For effective anti-tumour 
immunity, immune cells need to be in the tumour microenvironment, and a lack of immune 
cell infiltration could be detrimental to the establishment of protective anti-tumour immunity. 
However, morphine has been shown to be protective in a murine Lewis lung carcinoma 
model by reducing immune cell infiltration and angiogenesis (Koodie et al., 2014). Morphine 
can also elicit anti-tumour effects that are mediated via modulation of paracrine 
communication between cancer cells and non-malignant cells in the tumour 
microenvironment (Afsharimani et al., 2014), and can prevent the pro-angiogenic interaction 
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between macrophages and breast cancer cells (Khabbazi et al., 2016). Furthermore, morphine 
modulates cells in the tumour microenvironment via many mechanisms, some of which 
increase and others decrease tumour aggressiveness (Khabbazi et al., 2015). 
However, it should be noted that not all immune cells are beneficial to the anti-tumour 
response. Immunosuppressive ‘regulatory’ T cell populations can suppress the immune 
response (Takeuchi et al., 2016), and meta-analyses have reported increased regulatory T cell 
infiltration into breast cancers is associated with a poorer survival (Shou et al., 2016; Wang et 
al., 2016). Incubating blood from patients with gastric or breast cancer with morphine, 
sufentanil or fentanyl in vitro increases the number of regulatory T cells (Gong et al., 2014; 
Hou et al., 2016). Furthermore, although peri-operative treatment of women undergoing 
breast cancer resection with sufentanil or fentanyl equally decreased regulatory T cell 
numbers at day 1, numbers were increased on day 7 (Gong et al., 2014). Given the capacity 
of regulatory T cells to inhibit anti-tumour immunity, these effects could therefore be 
detrimental (Takeuchi et al., 2016).  
 
Animal studies: Anti-tumour immunity and tumour growth 
Many studies have described how opioids can affect immunity, most of which have been 
based on the acute administration of morphine. However, the duration of opioid 
administration (as well as the opioid itself) are likely to differential effects on immune 
function (Liang et al., 2016; Xie et al., 2017). 
NK cells are key participants in effective tumour immunosurveillance. Suppression of NK 
cell cytotoxicity correlates with increased tumour growth and metastasis in animal models 
(Franchi et al., 2007; Gaspani et al., 2002; Shavit et al., 2004). The literature generally 
reports that morphine (Franchi et al., 2007; Yeager et al., 1995) and fentanyl (Franchi et al., 
2007; Martucci et al., 2004; Shavit et al., 2004) decrease NK cell cytotoxicity, that 
buprenorphine does not affect NK cell cytotoxicity (Franchi et al., 2007; Martucci et al., 
2004) and that tramadol enhances it (Gaspani et al., 2002; Sacerdote et al., 2000) (Table 2). 
However, effects on NK cell cytotoxicity is likely to be dose-dependent, as low-dose 
morphine has been shown to stimulate cytotoxicity, and high-dose morphine to induce an 
initial increase in cytotoxicity followed by a suppression of cytotoxicity in pigs (Borman et 
al., 2009).  
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The differential effects of opioids on immune function and the development of tolerance is 
illustrated by a series of murine experiments by Martucci et al (Martucci et al., 2004). In 
these studies, single dose fentanyl only decreased lymphocyte proliferation, whereas chronic 
fentanyl reduced lymphocyte proliferation and splenic NK cell cytotoxicity, IL-2 and IFN- 
production at 24 hours. NK cell cytotoxicity recovered by day 3, whereas lymphocyte 
proliferation, IL-2 and IFN- production only recovered by day 7. After the 7-day infusion, 
the administration of twice the dose of fentanyl for 1 or 3 days to these mice did not affect 
any immune parameter, thereby suggesting that once developed, increasing the dose did not 
overcome immunological non-responsiveness (Martucci et al., 2004). In the same study, 
buprenorphine had no effect on any of the measured parameters at any time point (Martucci 
et al., 2004).  
The effect of the timing of morphine administration on cancer progression has been studied in 
a murine model of breast adenocarcinoma. If given before the development of cancer, 
morphine had no effect on cancer growth, whereas morphine increased the progression of 
established cancer and decreased survival via interactions with tumour µ-opioid receptors 
(Nguyen et al., 2014).  
Several surgery-based studies have assessed how different opioids, and the timing of opioid 
administration, affect cancer progression. In a series of rodent experiments, Franchi and co-
workers showed that morphine and fentanyl decreased NK cell cytotoxicity and increased 
MADB106 cell-derived lung metastases, whereas buprenorphine did not (Franchi et al., 
2007). Surgery alone decreased NK cell cytotoxicity and increased MADB106 lung 
metastases. In the surgical model, perioperative buprenorphine reversed the suppressive 
effects of surgery on NK cell cytotoxicity and MADB106 lung metastases, whereas morphine 
and fentanyl did not (Franchi et al., 2007). Decreased NK cell cytotoxicity correlated with 
high corticosterone levels, thereby suggesting the involvement of the hypothalamic-pituitary-
adrenal axis (Franchi et al., 2007). Fentanyl has been shown to suppress NK cell cytotoxicity 
in rats, and this suppression correlates to increased tumour load when fentanyl is 
administered close to the time of MADB106 tumour cell inoculation, but not when fentanyl 
was administered 6 hours before tumour inoculation (Shavit et al., 2004). Thus, the acute 
administration of morphine and fentanyl around the time of tumour resection in animals 
could be detrimental to immune function and cancer outcomes. 
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In another series of rodent experiments, Gaspani et al demonstrated that tramadol increased, 
and morphine decreased NK cell cytotoxicity in non-operated rats (Gaspani et al., 2002). 
Surgery reduced NK cell cytotoxicity, and this reduction in cytotoxicity correlated with 
increased numbers of MADB106 cell-derived lung metastases. Morphine did not influence 
surgery-induced NK cell cytotoxicity suppression, whereas tramadol prevented this and 
reduced lung metastasis (Gaspani et al., 2002). The (+) enantiomer of tramadol inhibits 
serotonin uptake and is immunostimulatory, and this effect is inhibited by the serotoninergic 
antagonist metergoline (Sacerdote et al., 1999). It has also been shown that an increased 
serotoninergic tone stimulates NK cell cytotoxicity (Mossner et al., 1998). Thus, the effect of 
tramadol on NK cell cytotoxicity following surgery might be the summation of stimulation of 
NK activity, which is also present in non-operated rats, due to serotonin re-uptake inhibition, 
and the reduction of surgical pain which is itself immunosuppressive (Gaspani et al., 2002; 
Page, 2003; Page et al., 2001). For potentially immunosuppressive opioids, there could be a 
balance between the immunosuppressive effect of the opioid and the reduction of putative 
immunosuppression of pain (  
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Figure ) (Page, 2005).  
A recent study using mouse models of breast cancer has shown that perioperative morphine 
did not affect tumour growth, peripheral blood or tumour-infiltrating immune cells (although 
NK cells were not assessed), even when surgery was performed (Doornebal et al., 2015). The 
difference between this and the other presented studies, could be that the tumours in this 
study are grown in vivo and transplanted from mouse to mouse without being cultured on 
plastic, the orthotopic rather than intravenous inoculation of cancer cells, female mice being 
used (different species and genders could respond differently) and the 14-day dosing schedule 
of morphine which was initiated once mammary tumours had developed, or 1 day after 
mastectomy (Afsharimani et al., 2015; Doornebal et al., 2015). 
 
Healthy volunteer studies 
Several studies have assessed the effect of opioids in healthy volunteers (Table 2). These 
have the advantage of being able to evaluate the effect of opioids on both direct and indirect 
opioid-immune pathways in humans, as opposed to in vitro studies which can only assess 
direct pathways, albeit in a very controlled way (Boland et al., 2014a). However, it should be 
noted that healthy volunteer study results cannot necessarily be extrapolated to patients with 
cancer, as the inflammatory and immune cell activation context are different. 
In a volunteer study, morphine was shown to decrease NK cell cytotoxicity; with higher 
doses it took over 24 hr for the NK cell cytotoxicity to normalise after the morphine was 
stopped (Yeager et al., 1995). In two volunteer studies, acute administration of intravenous 
fentanyl increased NK cell cytotoxicity, an effect which resulted from an increase in the 
proportion of NK cells in the peripheral blood, rather than an increase in the cytotoxicity of 
individual NK cells (Yeager et al., 2002; Jacobs et al., 1999). Although these studies suggest 
that morphine suppresses NK cell cytotoxicity in healthy subjects, with a more prolonged 
suppression at a higher dose, and that fentanyl increases NK cell cytotoxicity, we cannot 
extrapolate healthy volunteer studies to the surgical/clinical setting. 
 
Human cancer surgical studies 
There is pre-clinical evidence that the immune response at the time of surgical removal of 
cancer is critical, that some opioids can be detrimental to the immune response and that this 
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can promote cancer progression (Byrne et al., 2016; Gaspani et al., 2002; Shavit et al., 2004). 
As in vitro conditions of most studies do not reproduce the biology of cancer in vivo, and that 
there are differences between opioids (Borner et al., 2013), immune response and clinical 
outcomes to different opioids need to be studied in humans undergoing surgical resection of 
cancer. During surgery, opioids are just one of many factors that might affect cancer 
progression/metastasis (Byrne et al., 2016). Opioids also influence cancer growth in animal 
models via numerous mechanisms, with the potential influence on anti-tumour immunity 
being just one of these (Afsharimani et al., 2011; Gach et al., 2011; Jaura et al., 2014). 
In patients undergoing surgery, surgical stress variably reduces NK cell cytotoxicity, and 
different opioids (and the dose used) have different effects on NK cell cytotoxicity. In 30 
patients undergoing surgery for uterine carcinoma to whom were administered fentanyl, 
anaesthetic medications and either morphine or tramadol, NK cell cytotoxicity was not 
affected by the surgery or by morphine (trend for inhibition only). However, tramadol 
increased NK cell cytotoxicity at 2 hours post-treatment, despite similar analgesia (Sacerdote 
et al., 2000). In a randomised controlled trial of 40 patients undergoing surgery for malignant 
or benign conditions, post-operative NK cell cytotoxicity was reduced, with high-dose 
fentanyl delaying the post-operative recovery of NK cell cytotoxicity (Beilin et al., 1996). 
The long-term impact or overall outcome of different opioids and doses were not determined. 
The influence of morphine with or without flurbiprofen (the flurbiprofen group consumed 
less morphine) on immune status has been evaluated in 60 patients undergoing surgery for 
gastric cancer. In the morphine treated patients, T and NK cell numbers decreased at 2 hours 
after incision, and NK cell numbers had not returned to baseline at 5 days after surgery. In the 
flurbiprofen group, NK cell numbers at 2 hours and T and NK cell numbers at 1 day were 
higher, despite similar levels of analgesia (Shen et al., 2014). In a randomised controlled trial 
of 25 patients undergoing neck surgery, fentanyl suppressed NK cell cytotoxicity more than 
flurbiprofen on day 1, but not day 2 postoperatively (Narahara et al., 2013). The difference 
could either be a beneficial effect of the flurbiprofen or a negative effect of the opioid 
(Boland et al., 2016a; Hooijmans et al., 2015). 
Although NK cell cytotoxicity correlates with tumour growth and metastasis in animal 
models, cancer outcomes have not been assessed in human cancer surgery settings (Table 2). 
Furthermore, the magnitude of change in NK cell cytotoxicity which is needed to produce a 
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clinically-relevant effect is unknown. It is therefore difficult to definitively attribute a 
decrease in NK cell cytotoxicity to poorer outcomes in patients with cancer. 
 
Systemic opioid sparing surgical studies 
Many studies have assessed the effects of regional analgesia vs. systemic opioids on clinical 
outcomes. In general, these compare clinical outcomes between pain control with 
regional/neuraxial analgesia and systemic opioids in patients having cancer surgery.  
Meta-analyses for the effect of neuraxial blockade on cancer surgery have generated mixed 
findings from the heterogeneous and mostly retrospective studies that were included. One 
concluded that there was no advantage for overall or progression-free survival (Cakmakkaya 
et al., 2014), whereas another suggested there might be a benefit for neuraxial blockade for 
prostate cancer surgery, but not for colonic cancer (Pei et al., 2014). The most recent and 
largest meta-analysis (incorporating findings from 21 studies) reported an association 
between improved recurrence-free and overall survival with neuraxial anaesthesia (compared 
to general anaesthetic alone), especially in patients having colorectal cancer surgery (Weng et 
al., 2016). 
Many reviews have considered the various perioperative factors which might influence 
cancer-related outcomes. They suggest that although pre-clinical studies indicate a benefit of 
regional anaesthesia and stress response reduction in cancer formation, there is no clear 
association between regional/neuraxial anaesthesia for cancer surgery and tumour recurrence 
and cancer-related survival benefit from the heterogeneous and mostly retrospective studies. 
However, there might be an association with improved overall survival (Sun et al., 2015; 
Vogelaar et al., 2016). This needs confirmation and causality explored in prospective studies.  
A randomised controlled trial of 503 patients undergoing abdominal surgery for cancer 
resection compared the effect of general anaesthesia with either epidural analgesia or 
postoperative systemic opioids (median 3-day morphine dose: 0mg epidural group; 107mg 
opioid group) showed no difference in cancer recurrence and mortality at 2-3 years between 
the two groups (Myles et al., 2011). In a prospective cohort study of 34,188 cancer survivors 
who had resections for early stage breast cancer, opioid prescriptions were not associated 
with breast cancer recurrence (Cronin-Fenton et al., 2015). This echoes previous studies 
indicating that opioids do not increase de novo cancer risk. 
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As surgical stress response and increased glucocorticoids can cause immune suppression, 
some of the benefits from regional anaesthesia may result from better analgesia (reducing 
pain-associated immune suppression), along with attenuation of the surgical stress response, 
decreases in levels of endogenous opioids and the lower doses of systemic opioids (Al-
Hashimi et al., 2013; Byrne et al., 2016; Juneja, 2014). 
Data on the influence of opioid-sparing techniques for the surgical resection of cancer are 
mixed, and are primarily derived from retrospective studies. Although the most recent meta-
analysis reported an association between improved recurrence-free and overall survival with 
neuraxial anaesthesia (Weng et al., 2016), more randomised controlled trials are needed in 
different cancers to elucidate causation, some of which are underway (Buggy et al., 2015; 
Byrne et al., 2016; Connolly et al., 2016). In the meantime, there is consensus that there is 
currently insufficient evidence to change perioperative practice until the results of definitive 
randomised controlled trials are available (Buggy et al., 2015; Byrne et al., 2016; Connolly et 
al., 2016). 
 
 
 
Effects of opioids on anti-tumour immunity and survival in patients with cancer  
Many patients who are not undergoing surgery receive long-term opioids for cancer-related 
pain, which is a different scenario in terms of the immune effects of opioids and their clinical 
consequences. 
Effects of opioids on immunological parameters that are relevant to anti-tumour immune 
potential in patients with cancer have been reviewed previously (Boland et al., 2014b). Five 
human studies which assessed the immune effects of morphine in patients with cancer 
showed variable effects on immunologic end points. Given that none of these studies 
measured the clinical effects, it is not possible to know the clinical significance of these 
(Boland et al., 2014b). 
Opioids, via immune (and non-immune) effects can influence cancer progression in animal 
studies and other patient groups. The effect of opioids on prognosis in patients with cancer 
not undergoing surgery has been systematically reviewed (Boland et al., 2015). In the 13 
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studies of patients in the last days/weeks of life, there were mixed effects of opioids on 
survival. These studies were short term with poor methodology, sometimes only including 
patients with a very limited life expectancy such as from hospice admission, or only 
measured opioids that were taken in the last day(s) of life (Boland et al., 2015). The best 
quality end of life study, a secondary data analysis, showed that an intravenous morphine-
equivalent dose (IVME) above 20 mg/day was associated with a shorter survival compared 
with ≤17 mg/ day (the lowest dose group); mean survival: 27 days for patients on ≤17 mg/day 
IVME vs 12 days for patients on 20-25 mg/day IVME (Portenoy et al., 2006). Studies in 
patients with a longer prognosis (months to years) tended to be larger and of better quality. 
Six out of seven studies described an association between strong systemic opioid use or 
increasing dose and shorter survival. However, these studies did not have survival as a 
primary, appropriately powered, endpoint. Furthermore, they were limited, in that they 
included variable populations, starting points for opioid use, durations of opioid 
administration and from when survival was measured. The main confounding factor is that 
the control groups were not directly matched (i.e. not patients who had refractory severe 
symptoms, but did not choose opioids), and that greater analgesic requirements and shorter 
survival is likely to be mediated by painful progressive cancer. As a consequence, these 
studies cannot show causality, only associations (Boland et al., 2015). 
Pharmacogenetic factors are also important. In 2039 women with breast cancer, the A118G 
MOP receptor polymorphism, which confers a reduced receptor response to opioids, was 
associated with increased cancer-related survival in invasive breast cancer (Bortsov et al., 
2012). Although, opioid consumption was not recorded, patients with the A118G 
polymorphism need a higher morphine dose for analgesia. It is thus likely that the A118G 
patients received more opioids and had increased cancer–related survival (Bortsov et al., 
2012). Furthermore, Chinese people with the A118G MOP receptor polymorphism had a 
lower incidence of oesophageal cancer (Wang et al., 2013). However, this might be cancer-
type dependent, as North-eastern Polish patients with the A118G allele are more likely to 
develop breast cancer (Cieslinska et al., 2015). 
 
Future studies 
The variable findings from in vitro, animal or healthy volunteers cannot be extrapolated to 
clinical settings, between the different clinical settings or between opioids (Juneja, 2014; 
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Ramaswamy et al., 2017). Therefore, appropriate prospective studies in each of the clinical 
settings in which are used are required. These need to focus on long-term clinical studies and 
be undertaken in patients needing long-term continuous and intermittent opioids for non-
surgical cancer-related pain, in specific cancer types (Xie et al., 2017). They should also 
elucidate mechanisms by analysing the tumours for mitogenic activity, immune cell status in 
circulation and tumours, pain, symptoms and survival-related outcomes. In vitro, animal and 
healthy volunteer studies should principally be used to explore mechanisms, as the 
environments can be carefully controlled. These should use clinically relevant conditions, 
including opioid concentrations, in the experimental design (Boland et al., 2016b). 
Furthermore, subset analysis of NK cells is needed (as CD56bright and CD56dull NK cells 
exhibit different functionality) (Tabellini et al., 2014), and pharmacogenomics, such as the 
A118G MOP receptor polymorphism, should be taken into account. 
Patients taking opioids for cancer-related pain could be on opioids for a long time, thus 
tolerance could develop. Given that they might also be on opioids intermittently, it is 
important to know if regular or intermittent opioids are more immune protective and how this 
influences clinical outcomes. As pain is immunosuppressive, the effects of pain in patients 
and how opioids influence immunity and clinical outcomes in these populations need further 
study. Appropriately designed and powered studies assessing clinical outcomes of opioid use 
in patients with cancer are required to inform the optimal use of opioids in these patient 
groups.  
 
Conclusion  
Evidence from preclinical, healthy volunteer, clinical and surgical models suggests that 
different opioids variably influence protective anti-tumour immunity. There are discrepancies 
in the results of these studies which might be partly explained by differing methodologies, 
species used, opioid used and the dose and duration of administration. However, in general 
the literature reports that morphine and fentanyl decrease NK cell cytotoxicity in vivo 
(although short-term in vivo exposure to fentanyl in healthy humans increases NK cell 
numbers and cytotoxicity), buprenorphine does not affect NK cell cytotoxicity and tramadol 
enhances it. This change in NK cell cytotoxicity correlates with tumour growth and 
metastasis in rodent models. Opioid dose and duration of administration can influence 
outcome. 
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Although clinical evidence is sparse, data suggest that perioperative opioid sparing may lead 
to better long-term outcomes. However, high-quality perioperative and chronic cancer-related 
pain studies are needed. Given that current data from patients with cancer are inconclusive, 
definitive recommendations about how adequate analgesia is best achieved cannot be made 
and opioids for cancer-related pain will continue to be recommended. 
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Figures and figure legends 
 
Figure 1: Peripheral and central mechanisms of opioid-induced immune suppression.  
Opioids can have direct effects on immune cells which express appropriate receptors such as 
mu opioid peptide (MOP) receptors and Toll-like receptor-4 (TLR-4). They can also have 
immunosuppressive effects via central mechanisms. Acute opioid administration enhances 
activity in the periaqueductal gray (PAG) matter which activates the sympathetic nervous 
system (SNS). The SNS innervates lymphoid organs, such as the spleen, and this activation 
induces the release of biological amines which suppress splenic lymphocyte proliferation and 
NK cell cytotoxicity (Fecho et al., 1996; Irwin et al., 1988). Second, prolonged use of opioids 
increases hypothalamic pituitary adrenal (HPA) axis activity and glucocorticoid production, 
which decrease NK cell cytotoxicity (Fecho et al., 1996; Mellon et al., 1998). Morphine can 
also act via D1 dopamine receptors in the nucleus accumbens shell, increasing the release of 
neuropeptide Y (NPY) and reducing splenic NK cell cytotoxicity in rodent models (Saurer et 
al., 2006). Reproduced from (Boland et al., 2014b) with permission by British Journal of 
Cancer; http://www.nature.com/bjc/journal/v111/n5/full/bjc2014384a.html. 
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Figure 2: Opioids, pain, immunity and cancer.  
Pain is immunosuppressive and may worsen outcomes in rodent models of cancer (Page, 2003; 
Page et al., 2001). By reducing pain, opioids might have a beneficial effect on immune function 
and cancer (Gaspani et al., 2002; Page, 2005). However, opioids which suppress immune 
function may decrease anti-tumour immunity and promote the development of cancer; the 
balance of these effects is critical (Shavit et al., 2004).  
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Tables 
Table 1: Role and function of the main immune cells. 
Cell Role Function  Arm 
Dendritic cell Antigen 
presentation 
Presentation of antigenic peptides in 
the context of MHC class I and II 
molecules and the delivery of 
essential co-stimulatory molecules 
Innate 
Natural killer cell Anti-tumour 
Anti-viral 
 
Release of cytotoxic molecules 
(granzymes, perforin)  
Innate 
Neutrophil Anti-bacterial / 
fungal  
Phagocytosis and oxidative burst Innate 
Monocyte- 
Macrophage lineage 
Anti-bacterial / 
fungal 
Phagocytosis and oxidative burst Innate 
CD4+ T cell Immune 
coordination / 
regulation 
Regulating the activity of other 
immune cells 
Adaptive 
Regulatory T cell 
(CD4+, CD25+, 
FOXP3+, CD127low, 
plus other markers) 
Immune 
regulation/ 
suppression 
Immune system modulation, 
maintaining tolerance to self-
antigens, preventing autoimmune 
disease, potential barrier to the 
development of protective anti-
tumour immunity 
Adaptive 
CD8+ T cell Cytotoxicity Eradication of virally-infected cells 
and cancer cells. Induction of 
apoptosis by 
i) release of cytotoxins (perforin, 
granulysin, granzymes)  
ii) direct cell-cell contact  
Adaptive 
B cell Antibody 
production 
Antibody production Adaptive 
Adapted with permission by British Journal of Cancer from (Boland et al., 2014b); 
http://www.nature.com/bjc/journal/v111/n5/full/bjc2014384a.html. 
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Table 2: Summary of the effects of opioids on NK cell cytotoxicity and cancer outcomes 
in the different models  
 Animal  Healthy 
volunteer  
Human cancer 
surgery 
Opioid NK cell 
cytotoxicity 
Cancer  NK cell 
cytotoxicity 
NK cell 
cytotoxicity 
Cancer  
Morphine Decrease/no 
effect on 
suppressive 
effects of 
surgery 
Increase Decrease   No effect/ 
delayed 
post-
operative 
recovery 
Not 
assessed 
Fentanyl Decrease/no 
effect on 
suppressive 
effects of 
surgery 
Increase Increase Delayed 
post-
operative 
recovery  
Not 
assessed 
Buprenorphine No 
effect/reversed 
the suppressive 
effects of 
surgery 
No effect Not 
assessed 
No effect/ 
reversed the 
suppressive 
effects of 
surgery 
Not 
assessed 
Tramadol Increase/reversed 
the suppressive 
effects of 
surgery 
Decrease  Not 
assessed 
Increase/ 
reversed the 
suppressive 
effects of 
surgery 
Not 
assessed 
 
 
